Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KuicK Research | PRODUCT CODE: 1059647

Cover Image

PUBLISHER: KuicK Research | PRODUCT CODE: 1059647

Global Cancer Antibody Drug Conjugate Market, Drug Sales, Price, & Clinical Trials Insight 2028

PUBLISHED:
PAGES: 800 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3600
PDF (Multi-User License)
USD 6000

Add to Cart

“Global Cancer Antibody Drug Conjugate Market, Drug Sales, Price, & Clinical Trials Insight 2028” Report Highlights:

  • Global Cancer Antibody Drug Conjugate Market Opportunity > USD 25 Billion
  • Global Market Sales Trends & Market Forecast Till 2028
  • Clinical Insight On 18 Approved Cancer Antibody Drug Conjugates
  • Dosage, Price & Patent Insight On 18 Cancer Antibody Drug Conjugate
  • Quarterly & Yearly Drug Sales Insight & Forecast Till 2028
  • Clinical Insight On More Than 400 Cancer Drug Conjugates In Clinical Trials
  • Competitive Landscape

Global Cancer Antibody Drug Conjugate Market Analysis by County:

US, Europe, Japan, China, South Korea, India, Australia, Taiwan, Canada.

Global Cancer Antibody Drug Conjugate Market by Indication:

Breast Cancer, Lymphoma, Leukemia, Multiple Myeloma, Gastric Cancer, Lung Cancer.

Antibody drug conjugates are the emerging class of cancer targeting drugs which are built by attaching a small cytotoxic agent to an antibody via linker. The antibody targets the specific antigen which is presence on the targeted cell and delivers the cytotoxic payload. The novel therapeutic class delivers the drug with very high specificity to the target cell, maximizing the efficacy and minimizing systemic exposure. The entrance of antibody drug conjugates for the management of cancer has shown to greatly revolutionize the paradigm of cancer therapy in short span of time.

Presently, only 18 antibody drug conjugates have been approved by regulatory bodies for the management of various cancers including breast cancer, leukemia, lymphoma, multiple myeloma, gastrointestinal, and urothelial cancers. The breast cancer segment contributes to a majority of share in the market owing to the large number of product approved, increasing prevalence of breast cancer, and robust sales worldwide. However, it is estimated that during the forecast period lymphoma antibody drug conjugate segment will register high growth rates which is mainly attributed to large number of ongoing clinical trials, and new product launches during the forecast period. For instance, US FDA has recently granted permission to initiate phase-III clinical trial of Zilovertamab in relapsed/refractory mantle cell lymphoma. Zilovertamab developed by Oncternal Therapeutics is novel antibody drug conjugate targeting ROR1.

The encouraging response of antibody drug conjugates in the management of cancer has further drive the research and development activities in this domain. The global market has diverse players which are involved in fierce competition. The research activities lead to new discoveries and treatment options, eventually adding value to the growth of the antibody drug conjugate market. The major key players in the market include Daiichi Sankyo, Roche, Gilead Sciences, ADC Therapeutics, AstraZenca, Seagen, Takeda Pharmaceuticals, and others. In addition to this, several small start-ups have also entered into license agreement with big pharmaceutical giants to maintain their position in the global market. These rising trends in the market points towards the positive future of antibody drug conjugates in cancer therapeutics.

Apart from monotherapy, several ongoing clinical trials are also evaluating the role of antibody drug conjugates in combinational therapy to enhance the overall efficacy and to overcome drug resistance. For instance, Gilead Sciences has entered into collaboration with Merck to evaluate the combination of Trodelvy and Keytruda in first-line metastatic non-small cell lung cancer. Furthermore, researchers are also expanding the knowledge of antibody drug conjugate in targeting other diseases such as rheumatoid arthritis. AbbVie has developed ABBV-3373 which has shown significant improvement in patient with rheumatoid arthritis. The coming years will witness increased use of antibody drug conjugate in oncological as well as non-oncological conditions which will drive the growth of market.

As per our report findings, the global antibody drug conjugate market is expected to surpass US$ 25 Billion by 2028, thus registering high CAGR rates. Rising geriatric population associated with high cancer prevalence is one of the major factors which will influence the growth of market. In addition, other factors such as unmet need of targeted cancer therapy, increasing awareness about availability of antibody drug conjugates, rising investments by pharmaceutical companies, development of favorable reimbursement policies, and new product launches will also aid in the growth of market during the forecast period.

The report provides comprehensive analysis on the currently available antibody drug conjugates in the market with their commercial information. The report also provides insights into ongoing clinical trials and major antibody drug conjugates in the development, which is expected to enter the market during the forecast period. Apart from this, competitive analysis and major trends ongoing in the market are also included in the report.

Table of Contents

1. Introduction to Antibody Drug Conjugates (ADCs)

  • 1.1. Overview
  • 1.2. Historical Development of ADCs

2. Evolution of Antibody Drug Conjugates

  • 2.1. Advancements in ADCs
    • 2.1.1. First Generation
    • 2.1.2. Second-Generation
    • 2.1.3. Third Generation
  • 2.2. Components of ADCs
    • 2.2.1. Monoclonal Antibodies (mAbs)
    • 2.2.2. Linkers
    • 2.2.3. Payloads

3. Antibody Drug Conjugates-Mechanism of Action

  • 3.1. Antigen-Antibody Interaction
  • 3.2. Release of Payload
  • 3.3. Mechanism of Cytotoxicity

4. Need of Antibody Drug Conjugates

5. Role of ADCs in Cancer Management

  • 5.1. Breast Cancer
  • 5.2. Leukemia
  • 5.3. Lymphoma
  • 5.4. Other Cancers

6. Antibody Drug Conjugates-Availability, Dosage & Price Analysis

  • 6.1. Mylotarg
  • 6.2. Adectris
  • 6.3. Kadcyla
  • 6.4. Besponsa
  • 6.5. Lumoxiti
  • 6.6. Polivy
  • 6.7. Enhertu
  • 6.8. Padcev
  • 6.9. Trodelvy
  • 6.10. Blenrep
  • 6.11. Zynlonta
  • 6.12. Tivdak
  • 6.13. Aidixi
  • 6.14. Ujvira
  • 6.15. Akalux

7. Antibody Drug Conjugate-Sales Insights & Forecast 2028

  • 7.1. Adcetris
  • 7.2. Padcev
  • 7.3. Tivdak
  • 7.4. Polivy
  • 7.5. Kadcyla
  • 7.6. Besponsa
  • 7.7. Enhertu
  • 7.8. Trodelvy
  • 7.9. Zynlonta
  • 7.10. Blenrep

8. Global Antibody Drug Conjugate Market

  • 8.1. Current Market Scenario
  • 8.2. Future Market Opportunity

9. Antibody Drug Conjugate Market Regional Analysis

  • 9.1. US
  • 9.2. Europe
  • 9.3. Japan
  • 9.4. China
  • 9.5. South Korea
  • 9.6. India
  • 9.7. Australia
  • 9.8. Taiwan
  • 9.9. Canada

10. Antibody Drug Conjugate Market by Indication

  • 10.1. Breast Cancer
  • 10.2. Lymphoma
  • 10.3. Leukemia
  • 10.4. Multiple Myeloma
  • 10.5. Gastric Cancer
  • 10.6. Lung Cancer

11. Global Antibody Drug Conjugates Clinical Trials Insight 2022-2028

  • 11.1. By Phase
  • 11.2. By Indication
  • 11.3. By Company
  • 11.4. By Patient Segment
  • 11.5. By Country

12. Global Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication & Phase

  • 12.1. Research
  • 12.2. Preclinical
  • 12.3. Clinical
  • 12.4. Phase-0
  • 12.5. Phase-I
  • 12.6. Phase-I/II
  • 12.7. Phase-II
  • 12.8. Phase-II/III
  • 12.9. Phase-III
  • 12.10. Preregistration
  • 12.11. Registered

13. Marketed Cancer Antibody Drug Conjugates Insight

14. Global Cancer an Antibody Drug Conjugates Market Dynamics

  • 14.1. Favorable Parameters
  • 14.2. Challenges for Antibody Drug Conjugates Market

15. Antibody Drug Conjugates Market-Future Outlook

16. Competitive Landscape

  • 16.1. AstraZeneca plc
  • 16.2. Genentech
  • 16.3. Roche
  • 16.4. Takeda Pharmaceuticals
  • 16.5. Pfizer
  • 16.6. Oxford BioTherapeutics
  • 16.7. Heidelberg Pharma
  • 16.8. Synthon
  • 16.9. Mersana Therapeutics
  • 16.10. Progenics Pharmaceuticals
  • 16.11. Astellas Pharma
  • 16.12. Bristol Mayer Squibb
  • 16.13. Seattle Genetics
  • 16.14. Immunogen
  • 16.15. Celldex Therapeutics

List of Figures

  • Figure 1-1: Historical Development of Antibody-Drug Conjugate
  • Figure 1-2: Approval History of Commercially Available Antibody-Drug Conjugates
  • Figure 2-1: Classification of Antibody-Drug Conjugates
  • Figure 2-2: Components of Antibody-Drug Conjugates
  • Figure 2-3: Antigen Expression Analyzing Techniques used in Development of ADCs
  • Figure 2-4: Isotypes of Monoclonal Antibodies used in ADC Development
  • Figure 2-5: Classification of Linkers
  • Figure 2-6: Types of Cleavable Linkers
  • Figure 2-7: Non-Cleavable Linker Used in ADCs Development
  • Figure 2-8: Cytotoxic drugs used in Antibody Drug Conjugates
  • Figure 3-1: General Mechanism of Antibody Drug Conjugates against Cancer
  • Figure 3-2: ADCs - Antigen-Antibody Interaction in Normal & Cancerous Cells
  • Figure 3-3: Releasing Mechanism of Payloads
  • Figure 3-4: Mechanism of Cytotoxicity via Alkylating Agents
  • Figure 3-5: Mechanism of Toxicity via Tubulin Inhibitors
  • Figure 4-1: Therapeutic Index - Antibody Drug Conjugate vs. Cytotoxic Drug
  • Figure 6-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
  • Figure 6-2: Mylotarg - Approval Year by Region
  • Figure 6-3: UK - Cost of Supply of Mylotarg 5mg Intravenous Powder (GBP/US$), January'2022
  • Figure 6-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), January'2022
  • Figure 6-5: Mylotarg - Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
  • Figure 6-6: Mylotarg - Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), January'2022
  • Figure 6-7: Mylotarg - Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
  • Figure 6-8: Mylotarg - Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
  • Figure 6-9: Mylotarg - Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
  • Figure 6-10: Mylotarg - Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), Janauary'2022
  • Figure 6-11: Mylotarg - Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, January'2022
  • Figure 6-12: US - Adcetris Oprhan Drug Designation Approval Year by Indication
  • Figure 6-13: US - Adcetris FDA Approval Year by Indication
  • Figure 6-14: Adcetris - Approval Year by Region
  • Figure 6-15: Japan - Adcetris FDA Approval Year by Indication
  • Figure 6-16: Adcetris - Patent Expiration by Region
  • Figure 6-17: UK - Cost of Supply of Adcetris 50mg Intravenous Powder (GBP/US$), January'2022
  • Figure 6-18: Adcetris - Cost of Supply of Vial for Injection by Region (US$), January'2022
  • Figure 6-19: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
  • Figure 6-20: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), January'2022
  • Figure 6-21: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)
  • Figure 6-22: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US$), January'2022
  • Figure 6-23: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), January'2022
  • Figure 6-24: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks)
  • Figure 6-25: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), January'2022
  • Figure 6-26: US - Kadcyla FDA Approval Year by Indication
  • Figure 6-27: Kadcyla - Approval Year by Region
  • Figure 6-28: US - Kadcyla FDA Approval & Patent Expiration Year
  • Figure 6-29: US - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (US$), January'2022
  • Figure 6-30: UK - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (GBP/US$), January'2022
  • Figure 6-31: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
  • Figure 6-32: Kadcyla - Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), January'2022
  • Figure 6-33: Kadcyla - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
  • Figure 6-34: Besponsa - Approval Year by Region
  • Figure 6-35: UK - Cost of Supply of Besponsa 0.9mg Intravenous Powder (GBP/US$), January'2022
  • Figure 636: Besponsa - Cost of Supply of Vial for Injection by Region (US$), January'2022
  • Figure 6-37: Besponsa - Duration of Initial Treatment Cycle & Subsequent Cycles (Days)
  • Figure 6-38; Besponsa - Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2)
  • Figure 6-39: Besponsa - Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), January'2022
  • Figure 6-40: Besponsa - Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), January'2022
  • Figure 6-41: Besponsa - Duration of Treatment of ALL - After & Without HSCT (Weeks)
  • Figure 6-42: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
  • Figure 6-43: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks)
  • Figure 6-44: Lumoxitin - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January'2022
  • Figure 6-45: Polivy - Orphan Drug Designation Approval Year by Region
  • Figure 6-46: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
  • Figure 6-47: Polivy - Approval Year by Region
  • Figure 6-48: US - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (US$), January'2022
  • Figure 6-49: UK - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (GBP/US$), January'2022
  • Figure 6-50: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)
  • Figure 6-51: Polivy - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January'2022
  • Figure 6-52: US - Enhertu Orphan Drug Designation Approval & Exclusivity Year
  • Figure 6-53: Enhertu - Approval Year by Region
  • Figure 6-54: US - Polivy FDA Approval Year by Indication
  • Figure 6-55: UK - Cost of Supply of Enhertu 100mg Intravenous Powder (GBP/US$), January'2022
  • Figure 6-56: Besponsa - Cost of Supply of Vial for Injection by Region (US$), January'2022
  • Figure 6-57: Enhertu - Recommended Dose by Cancer Type (mg/Kg)
  • Figure 6-58: Enhertu - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
  • Figure 6-59: Enhertu - Recommended Dose & Dose after Reduction for Breast Cancer (mg/Kg)
  • Figure 6-60: Enhertu - Recommended Dose & Dose after Reduction for Gastric Cancer (mg/Kg)
  • Figure 6-61: Padcev - Approval Year by Region
  • Figure 6-62: US - Padcev FDA Approval & Patent Expiration Year
  • Figure 6-63: US - Price for Padcev 20mg & 30mg Intravenous Powder for Injection (US$), January'2022
  • Figure 6-64: Padcev - Average Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), January'2022
  • Figure 6-65: Padcev - Recommended Minimum Dose & Dose after Reduction for Urothelial Cancer (mg/Kg)
  • Figure 6-66: Padcev - Recommended Maximum Dose & Dose after Reduction for Urothelial Cancer (mg)
  • Figure 6-67: US - Trodelvy FDA Approval by Indication
  • Figure 6-68: Trodelvy - Approval Year by Region
  • Figure 6-69: Trodelvy - Patent Expiration by Region
  • Figure 6-70: Trodelvy - Average Cost of Single Dose, Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
  • Figure 6-71: Trodelvy - Recommended Dose & Dose after Reduction (mg/Kg)
  • Figure 6-72: US - Blenrep FDA Orphan Drug Designation & Approval Year
  • Figure 6-73: US - Blenrep FDA Orphan Drug Designation Approval & Patent Exclusivity Year
  • Figure 6-74: Europe - Blenrep FDA Orphan Drug Designation & Approval Year
  • Figure 6-75: Europe - Cost of Supply of Blenrep 100mg Intravenous Powder (Euro/US$), January'2022
  • Figure 6-76: Blenrep - Cost of Supply of Vial for Injection by Region (US$), January'2022
  • Figure 6-77: Blenrep - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
  • Figure 6-78: Blenrep - Recommended Dose & Dose after Reduction (mg/Kg)
  • Figure 6-79: US - Zynlonta FDA Orphan Drug Designation Approval & Patent Exclusivity Year
  • Figure 6-80: US - Zynlonta Orphan Drug Designation & FDA Approval Year
  • Figure 6-81: Zynlonta - Orphan Drug Designation by Region
  • Figure 6-82: Zynlonta - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
  • Figure 6-83: Zynlonta - Recommended Dose for Initial & Subsequent Cycles (mg/kg)
  • Figure 6-84: Tivdak - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
  • Figure 6-85: Tivdak - Maximum Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
  • Figure 6-86: Tivdak - Recommended Dose & Dose after Reduction (mg/Kg)
  • Figure 6-87: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
  • Figure 6-88: India - Price for Single Unit of Ujvira 100mg & 160mg Intravenous Powder for Injection (INR/US$), January'2022
  • Figure 6-89: India - Price for Single Unit of Branded & Biosimilar Trastuzumab Emtansine 100mg Powder for Injection (INR/US$), January'2022
  • Figure 6-90: Ujvira - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
  • Figure 6-91: Ujvira - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
  • Figure 6-92: Akalux - Sakigake Designation & PMDA Approval Year
  • Figure 7-1: Global - Adcetris Annual Sales (US$ Million), 2018 - 2021
  • Figure 7-2: Global - Adcetris Quarterly Sales (US$ Million), 2021
  • Figure 7-3: Global - Adcetris Quarterly Sales (US$ Million), 2020
  • Figure 7-4: Global - Adcetris Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-5: Global - Padecv Annual Sales (US$ Million), 2019 - 2021
  • Figure 7-6: Global - Padcev Quarterly Sales (US$ Million), 2021
  • Figure 7-7: Global - Padcev Quarterly Sales (US$ Million), 2020
  • Figure 7-8: Global - Padcev Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-9: Global - Tivdak Annual Sales (US$ Million), 2021 - 2028
  • Figure 7-10: Global - Polivy Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 7-11: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 7-12: US - Polivy Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 7-13: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 7-14: Japan - Polivy Quarterly Sales Value (US$/CHF Million), Q2-Q4'2021
  • Figure 7-15: ROW - Polivy Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 7-16: Polivy - Quarterly Sales Value by Region (US$/CHF Million), 2021
  • Figure 7-17: Polivy - Quarterly Sales Value by Region (%), 2021
  • Figure 7-18: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 7-19: US - Polivy Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 7-20: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 7-21: Polivy - Annual Sales Value by Region (US$/CHF Million), 2020
  • Figure 7-22: Polivy - Annual Sales Value by Region (%), 2020
  • Figure 7-23: Polivy - Quarterly Sales Value (US$/CHF Million), Q2-Q4'2019
  • Figure 7-24: Global - Polivy Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-25: US - Polivy Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-26: Europe - Polivy Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-27: Japan - Polivy Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-28: ROW - Polivy Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-29: Global - Kadcyla Annual Sales Value (US$/CHF Million), 2018 - 2021
  • Figure 7-30: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 7-31: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 7-32: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 7-33: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 7-34: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 7-35: Kadcyla - Quarterly Sales Value by Region (US$/CHF Million), 2021
  • Figure 7-36: Kadcyla - Quarterly Sales Value by Region (%),2021
  • Figure 7-37: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 7-38: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 7-39: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 7-40: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 7-41: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 7-42: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2020
  • Figure 7-43: Kadcyla - Annual Sales Value by Region (%). 2020
  • Figure 7-44: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 7-45: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 7-46: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 7-47: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 7-48: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 7-49: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2019
  • Figure 7-50: Global - Kadcyla Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-51: US - Kadcyla Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-52: Europe - Kadcyla Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-53: Japan - Kadcyla Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-54: ROW - Kadcyla Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-55: Global - Besponsa Annual Sales (US$ Million), 2020 & 2021
  • Figure 7-56: Global - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
  • Figure 7-57: US - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
  • Figure 7-58: Europe - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
  • Figure 7-59: ROW - Besponsa Quarterly Sales (US$ Million), 2020 & 2021
  • Figure 7-60: Besponsa - Annual Sales by Region (US$ Million), 2020 & 2021
  • Figure 7-61: Besponsa - Quarterly Sales by Region (%), 2020
  • Figure 7-62: Besponsa - Quarterly Sales by Region (%), 2021
  • Figure 7-63: Global - Besponsa Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-64: US - Besponsa Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-65: Europe - Besponsa Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-66: ROW - Besponsa Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-67: Global - Enhertu Annual Sales (US$ Million), 2020 & 2021
  • Figure 7-68: Global - Enhertu Quarterly Sales (US$ Million), 2021
  • Figure 7-69: Global - Enhertu Quarterly Sales (US$ Million), 2020
  • Figure 7-70: Global - Enhertu Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-71: Global - Trodelvy Annual Sales (US$ Million), 2020 & 2021
  • Figure 7-72: Global - Trodelvy Quarterly Sales (US$ Million), 2021
  • Figure 7-73: Trodelvy - Annual Sales by Region (US$ Million), 2021
  • Figure 7-74: Trodelvy - Annual Sales by Region (%), 2021
  • Figure 7-75: Global - Trodelvy Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-76: Global - Zynlonta Quarterly Sales (US$ Million), Q2 & Q3'2021
  • Figure 7-77: Global - Zynlonta Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-78: Global - Blenrep Annual Sales (US$ Million), 2020 & 2021
  • Figure 7-79: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2021
  • Figure 7-80: US - Blenrep Quarterly Sales (Euro/US$ Million), 2021
  • Figure 7-81: Europe - Blenrep Quarterly Sales (Euro/US$ Million), 2021
  • Figure 7-82: Blenrep - Quarterly Sales by Region (Euro/US$ Million), 2021
  • Figure 7-83: Blenrep - Quarterly Sales by Region (%), 2021
  • Figure 7-84: Global - Blenrep Quarterly Sales (Euro/US$ Million), 2020
  • Figure 7-85: Global - Blenrep Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-86: US - Blenrep Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-87: Europe - Blenrep Annual Sales (US$ Million), 2022 - 2028
  • Figure 7-88: ROW - Blenrep Annual Sales (US$ Million), 2022 - 2028
  • Figure 8-1: Global - Antibody Drug Conjugate Market (US$ Billion), 2020 & 2021
  • Figure 8-2: Antibody Drug Conjugate Market Size by Region (US$ Billion), 2021
  • Figure 8-3: Antibody Drug Conjugate Market Size by Region (%), 2021
  • Figure 8-4: Global - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
  • Figure 9-1: US - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 9-2: US vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
  • Figure 9-3: US vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
  • Figure 9-4: US - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
  • Figure 9-5: Europe - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 9-6: Europe vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
  • Figure 9-7: Europe vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
  • Figure 9-8: Europe - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
  • Figure 9-9: Japan - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 9-10: Japan vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
  • Figure 9-11: Japan vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
  • Figure 9-12: Japan - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
  • Figure 9-13: China - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 9-14: China vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
  • Figure 9-15: China vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
  • Figure 9-16: China - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
  • Figure 9-17: South Korea - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 9-18: South Korea vs. ROW - Antibody Drug Conjugate Market (US$ Billion), 2021
  • Figure 9-19: South Korea vs. ROW - Antibody Drug Conjugate Market (%), 2021
  • Figure 9-20: South Korea - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
  • Figure 9-21: India - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 9-22: India - Antibody Drug Conjugate Market Size (US$ Million), 2021 - 2028
  • Figure 9-23: Australia - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 9-24: Australia - Antibody Drug Conjugate Market Size (US$ Million), 2021 - 2028
  • Figure 9-25: Taiwan - Antibody Drug Conjugate Market Size (US$ Million), 2021 - 2028
  • Figure 9-26: Canada - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 9-27: Canada vs. ROW - Antibody Drug Conjugate Market Size (US$ Billion), 2021
  • Figure 9-28: Canada vs. ROW - Antibody Drug Conjugate Market Size (%), 2021
  • Figure 9-29: Canada - Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
  • Figure 10-1: Global - Breast Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 10-2: Global - Antibody Drug Conjugate Market Size by Indication (US$ Billion), 2021
  • Figure 10-3: Global - Antibody Drug Conjugate Market by Indication (%), 2021
  • Figure 10-4: Global - Breast Cancer Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
  • Figure 10-5: Global - Hodgkin & Non-Hodgkin Lymphoma Incidences (Million), 2020 & 2025
  • Figure 10-6: Global - Antibody Drug Conjugate Market Size by Indication (US$ Billion), 2021
  • Figure 10-7: Global - Antibody Drug Conjugate Market by Indication (%), 2021
  • Figure 10-8: Global - Lymphoma Antibody Drug Conjugate Market Size (US$ Billion), 2022 - 2028
  • Figure 10-9: Global - Leukemia Incidences & Deaths, 2020 & 2025
  • Figure 10-10: Global - Leukemia Antibody Drug Conjugate Market Size (US$ Billion), 2021 - 2028
  • Figure 10-11: Global - Multiple Myeloma Incidences & Deaths, 2020 & 2025
  • Figure 10-12: Global - Multiple Myeloma Antibody Drug Conjugate Market Size (US$ Billion), 2021 - 2028
  • Figure 10-13: Global - Gastric Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 10-14: Global - Gastric Cancer Antibody Drug Conjugate Market Size (US$ Billion), 2021 - 2028
  • Figure 10-15: Global - Lung Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 10-16: Global - Lung Cancer Antibody Drug Conjugate Market Size (US$ Billion), 2023 - 2028
  • Figure 11-1: Global - Antibody Drug Conjugate Clinical Pipeline by Phase (Numbers), 2022 till 2028
  • Figure 11-2: Global - Antibody Drug Conjugate Clinical Pipeline by Indication, 2022 till 2028
  • Figure 11-3: Global - Antibody Drug Conjugate Clinical Pipeline by Company, 2022 till 2028
  • Figure 11-4: Global - Antibody Drug Conjugate Clinical Pipeline by Patient Segment, 2022 till 2028
  • Figure 11-5: Global - Antibody Drug Conjugate Clinical Pipeline by Country, 2022 till 2028
  • Figure 14-1: Antibody Drug Conjugates Market Drivers
  • Figure 14-2: Challenges for Antibody Drug Conjugates Market
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!